Sources:

Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice. Neurotherapeutics, 12(1), 185–199. http://doi.org/10.1007/s13311-014-0304-z

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322067/)

Ladin, D. A., Soliman, E., Griffin, L., & Van Dross, R. (2016). Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. Frontiers in Pharmacology, 7, 361. http://doi.org/10.3389/fphar.2016.00361

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054289/)

Pagano EMontanaro VDi Girolamo APistone AAltieri VZjawiony JKIzzo AACapasso R. (2015). Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol. Nat Prod Commun. 2015 Jun;10(6):1009-12. (https://www.ncbi.nlm.nih.gov/pubmed/26197538)

Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4(1), 245–259. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/)

Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, and M. Mukhlesur Rahman. Antibacterial Cannabinoids from Cannabis sativa: A Structure−Activity Study.

Journal of Natural Products 2008 71 (8), 1427-1430

DOI: 10.1021/np8002673 (https://pubs.acs.org/doi/full/10.1021/np8002673)

Cascio, M., Gauson, L., Stevenson, L., Ross, R., & Pertwee, R. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129–141. http://doi.org/10.1111/j.1476-5381.2009.00515.x (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823359/)

Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1(7), 1333–1349. http://doi.org/10.4155/fmc.09.93

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828614/)

Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163(7), 1411–1422. http://doi.org/10.1111/j.1476-5381.2010.01176.x

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165951/)

Cunha J, M, Carlini E, A, Pereira A, E, Ramos O, L, Pimentel C, Gagliardi R, Sanvito W, L, Lander N, Mechoulam R, Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients. Pharmacology 1980;21:175-185

(https://www.karger.com/Article/Abstract/137430#)

Natalya M Kogan, Eitan Melamed, Elad Wasserman, Bitya Raphael, Aviva Breur.  Cannabidiol, a Major Non‐Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. American Society for Bone and Mineral Research, 2015.  https://doi.org/10.1002/jbmr.2513
(https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.2513)

Francisco J Alvarez, Hector Laufuente, M Carmen Rey-Santano,  Victoria E Mielgo, Elena Gastiasoro, Miguel Rueda, Roger G Pertwee, Ana I Castillo. Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets. Pediatric Research, 64, 653–658 (2008).

(https://www.nature.com/articles/pr2008260#author-information)

Cascio, M., Gauson, L., Stevenson, L., Ross, R., & Pertwee, R. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology159(1), 129–141. http://doi.org/10.1111/j.1476-5381.2009.00515.x

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823359/_

Giovannitti, J. A., Thoms, S. M., & Crawford, J. J. (2015). Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical Applications. Anesthesia Progress62(1), 31–38. http://doi.org/10.2344/0003-3006-62.1.31

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389556/)